Product
AUR108
1 clinical trial
1 indication
Indication
Relapsed Advanced LymphomasClinical trial
A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR108 in Patients With Relapsed Advanced Lymphomas(ASHA-1)Status: Recruiting, Estimated PCD: 2025-08-30